Hospital
acquired infections can create several complications for patients.
These infections, caused due to multidrug resistant organisms,
drastically reduce the convalescence of a patient and is often
accompanied with comorbidities.
Conventional
antibiotics fail to curb such infections, since these organisms are
multidrug resistant. Pneumonia is one of the most common infections
caused due to prolonged stays in hospital premises. Instances of
hospital acquired infections are most common among patients with weak
immunity, such as elderly and infant patients. Post-surgical
infections and infections caused due to enteral feeding constitute
the common cases of hospital acquired diseases. High prevalence of
hospital acquired pneumonia is likely to boost the pipeline for
hospital acquired pneumonia therapeutics.
To
study the prospects of the pipeline for global hospital acquired
pneumonia drugs Market, Transparency Market Research has released a
report titled “Pipeline Analysis of Hospital Acquired Pneumonia
Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends
and Forecast 2014 – 2020”. The report states that the six drugs
currently in phase III of testing are likely to generate total
revenue of US$3.8 billion by the end of 2020.
Browse
the full Pipeline Analysis of Hospital Acquired Pneumonia Drugs
Market Report at
http://www.transparencymarketresearch.com/hospital-acquired-pneumonia-drugs.html
The
report has identified that the stage III of pipeline analysis
currently has five investigational drugs and one vaccine. Ten other
candidates have successfully entered the early stages of pipeline
analysis. Drugs that have reached phase III of clinical trials
include AstraZeneca PLC’s Ceftazidime/avibactam, Achaogen, Inc’s
Plazomicin, GlaxoSmithKline’s Synflorix, Ceftolozane/tazobactam,
Bayer Healthcare’s Amikacin inhale, and Tedizolid phosphate by
Cubist Pharmaceuticals. If approved, these drugs could be available
in the market by 2017. The report has stated that mostly biological
drugs have entered the last stage of clinical trials. This shows a
paradigm shift from antibiotics drugs to novel biological drugs.
Increasing
incidence of drug resistance has emerged as a major concern among
hospitals around the world. The Centers of Disease Control and
Prevention (CDC) conducted a survey in the U.S., which revealed 63%
of Acinetobacter variants are multidrug resistant. Among the
hazardous organisms spurring ventilator-associated pneumonia,
methicillin-resistant Staphylococcus aureus (MRSA) is the most
prominent. According to the CDC, almost 80,400 MRSA infections were
registered in 2011, among which deaths of almost 11,000 patients were
reported. Additionally, it was also revealed by the World Health
Organization (WHO) that nosocomial infections are more common in low-
and middle-income economies. Hence, it is only obvious that the
situation regarding hospital acquired pneumonia is alarming in these
regions.
Browse
the full Press
Release:http://www.transparencymarketresearch.com/pressrelease/hospital-acquired-pneumonia-drugs.htm
The
report published by Transparency Market Research studies how the
spread of hospital acquired pneumonia will boost the pipeline of
hospital acquired pneumonia drugs. It includes region-based analysis
to study the prospects of the pipeline of hospital acquired pneumonia
drugs across key regions including North America, Europe, Asia
Pacific, and Rest of the World.
To
study the market competition, the report has profiled leading market
players such as GlaxoSmithKline, Achaogen, Inc., Cubist
Pharmaceutical, Bayer Healthcare, Aridis Pharmaceutical, Meiji Seika
Pharma Co., Ltd., AstraZeneca PLC, Valneva SE., Merck & Co., and
Basilea Pharmaceutica Ltd.
Hospital
Acquired Pneumonia, Pipeline Analysis Segments by Phase:
Phase
III
Tedizolid
phosphate
Ceftolozane/Tazobactam
Ceftazidime/Avibactum
Amikacin
Inhale
Plazomicin
Synflorix
Vaccine
Early
Phase (Phase I & II)
BAL30072
MEDI4893
AR-301
or KBSA301
AR-101
(or KBPA101) and AR-104 (or KBPA104)
AR-201
(or KBRV201)
AR-401
(or KBAB401)
ME1100
GSK
2189242A
V114
IC43
Pipeline
Analysis of Hospital Acquired Pneumonia Drugs Market Segmentation, By
Geography:
North
America
Europe
Asia
Pacific
Rest
of the World (RoW)
Request
a Brochure of this Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1881
About
Us
Transparency
Market Research (TMR) is a global market intelligence company
providing business information reports and services. The company’s
exclusive blend of quantitative forecasting and trend analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants
use proprietary data sources and various tools and techniques to
gather and analyze information.
TMR’s
data repository is continuously updated and revised by a team of
research experts so that it always reflects the latest trends and
information. With extensive research and analysis capabilities,
Transparency Market Research employs rigorous primary and secondary
research techniques to develop distinctive data sets and research
material for business reports.
No comments:
Post a Comment